TransMedics Group (NASDAQ:TMDX) Lowered to “Sell” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research downgraded shares of TransMedics Group (NASDAQ:TMDX) from a hold rating to a sell rating in a report released on Thursday morning, Zacks.com reports.

According to Zacks, “TransMedics Inc. is a commercial-stage medical technology company. It is engaged in transforming organ transplant therapy for end-stage organ failure patients. The company offers Organ Care System, an integrated, compact, portable preservation technology which addresses unmet need for organs for transplantation. TransMedics Inc. is headquartered in Andover, Massachusetts. “

Several other brokerages also recently commented on TMDX. Cowen began coverage on shares of TransMedics Group in a research report on Tuesday, May 28th. They set an outperform rating and a $40.00 price objective on the stock. Canaccord Genuity began coverage on shares of TransMedics Group in a research report on Tuesday, May 28th. They set a buy rating and a $37.00 price objective on the stock. Morgan Stanley began coverage on shares of TransMedics Group in a research report on Tuesday, May 28th. They set an equal weight rating on the stock. Finally, JPMorgan Chase & Co. began coverage on shares of TransMedics Group in a research report on Tuesday, May 28th. They set an overweight rating and a $34.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $37.00.

Shares of TMDX stock opened at $23.28 on Thursday. TransMedics Group has a one year low of $19.76 and a one year high of $31.54. The company’s fifty day moving average price is $23.70. The company has a debt-to-equity ratio of 0.48, a quick ratio of 6.82 and a current ratio of 7.55.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, June 12th. The company reported ($4.86) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by ($4.05). The firm had revenue of $4.68 million for the quarter, compared to analysts’ expectations of $4.43 million. On average, equities analysts forecast that TransMedics Group will post -1.95 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. NumerixS Investment Technologies Inc bought a new stake in shares of TransMedics Group during the 2nd quarter valued at $43,000. JPMorgan Chase & Co. bought a new stake in shares of TransMedics Group during the 2nd quarter valued at $50,000. Tower Research Capital LLC TRC bought a new stake in shares of TransMedics Group during the 2nd quarter valued at $190,000. Blackstone Group Inc bought a new stake in shares of TransMedics Group during the 2nd quarter valued at $290,000. Finally, Cubist Systematic Strategies LLC bought a new stake in TransMedics Group in the 2nd quarter valued at $314,000. Hedge funds and other institutional investors own 49.17% of the company’s stock.

About TransMedics Group

TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.

Read More: What is a Candlestick Chart?

Get a free copy of the Zacks research report on TransMedics Group (TMDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.